Recently, the reduced mROS levels in DCs impair their ability in cross-presentation and, consequently, in the culminating anti-tumor effect mediated by CD8+ T-cell response in vivo (58), suggesting a potential role of mROS in modulating protective immunity against tumor. Here, CD8A is linked to neoplasm.